Asia FX rises; US-Japan trade deal boosts yen, won to 2-week highs
Cardinal Health (NYSE:CAH) stock reached an all-time high of $166.33, marking a significant milestone for the healthcare services and products company. According to InvestingPro analysis, the company’s current market capitalization stands at $39.56 billion, with analysts setting price targets ranging from $127 to $197. Over the past year, Cardinal Health has experienced a remarkable 69.2% increase in its stock price, reflecting strong investor confidence and robust performance in the market. This surge can be attributed to the company’s strategic initiatives and operational efficiencies, which have resonated well with investors, propelling the stock to its current peak. The company’s financial health score of "GREAT" on InvestingPro and its 43-year track record of consistent dividend payments further validate its market position. As Cardinal Health continues to navigate the evolving healthcare landscape, this achievement underscores its growing influence and resilience in the sector. InvestingPro analysis suggests the stock may still have room to run, with additional insights available in the comprehensive Pro Research Report.
In other recent news, Cardinal Health has raised its full-year profit forecast, exceeding analyst expectations. The company now anticipates adjusted earnings per share (EPS) of $8.15 to $8.20 for the current fiscal year, up from the previous guidance of $8.05 to $8.15, surpassing the average analyst estimate of $8.14. Cardinal Health also provided preliminary guidance for fiscal year 2026, projecting adjusted EPS of $9.10 to $9.30, indicating a 13% growth at the midpoint. Meanwhile, Jefferies and UBS have both raised their price targets for Cardinal Health, with Jefferies setting it at $190 and UBS at $185, while maintaining a Buy rating. Jefferies noted the company’s defensive characteristics and growth drivers, while UBS highlighted the valuation compared to peers. Additionally, Cardinal Health announced strategic initiatives, including investments in Biopharma Solutions and a new distribution center, alongside increasing its baseline share repurchase plans to at least $750 million per year. The company aims to generate at least $10 billion in total adjusted free cash flow over the next three years. Cardinal Health’s Investor Day revealed a long-term target of 12% to 14% compound annual growth rate for adjusted EPS from fiscal years 2026 through 2028.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.